News
Eli Lilly is buying psychedelic-drug developer AtaiBeckley for up to $3.8 billion, its biggest bet yet on a novel treatment for hard-to-treat depression. The deal’s lead asset, BPL-003, showed a single dose can slash symptoms for months and has already won FDA breakthrough status.
News
The FDA has granted full approval to Eli Lilly’s RET inhibitor Retevmo for RET fusion-positive non-small cell lung cancer, broadening the label to include first-line patients. The decision, based on Phase III data, marks a key milestone for Lilly’s oncology portfolio.
News
Eli Lilly shares slipped 2.3% on Friday, but Wall Street analysts responded by raising price targets, with BofA lifting its to $1,334 and Truist to $1,370. The stock also got a lift from positive pipeline news, including an upcoming Kisunla data presentation and a favorable…
News
Eli Lilly’s Canadian unit scored a key win for its eczema drug Ebglyss, securing a positive reimbursement recommendation from the national drug agency and a letter of intent with the pan-Canadian alliance. The stock still closed down 2.33% on Wednesday.
News
A new analysis pits Eli Lilly’s explosive GLP-1 growth against Johnson & Johnson’s 60-year dividend streak, highlighting two starkly different investment styles in healthcare.